Luminii provides Commercial Due Diligence to 57Stars on their investment in Axial3D
Luminii are thrilled to have had the privilege of providing Commercial Due Diligence (CDD) support to 57Stars on their investment in Axial3D, a leader in creating AI-powered 3D medical imaging algorithms, automated planning and patient specific 3D solutions.
Founded in 2015 by Daniel Crawford, Axial3D has created an AI-powered service that can turn 2D medical images into patient-specific 3D models to address various medical purposes, such as pre-surgical planning, simulation, custom implants, medical device testing and custom prosthetics, as well as teaching and training.
In recent years, the company has opened a new 3D printing centre of excellence in Belfast and procured investment from additive manufacturing leader Stratasys. In 2023, the company also received FDA clearance for its AI-driven medical image segmentation platform.
As it receives this latest round of funding, the company is looking to accelerate its mission of making patient-specific medical solutions routine globally.
"Luminii are delighted to have supported 57Stars on this transaction. This is yet another deal that helps to strengthen our credentials in the Technology and Med-Tech/Healthcare sectors. We wish 57Stars and Axial3D continued success for the future." - Lushani Kodituwakku, Managing Director, Luminii Consulting
Latest articles
- Luminii provides CDD support to Octopus and Riverside on their investment in ThreatMark 10 Jan 2025
- Luminii provides Commercial Due Diligence to 57Stars on their investment in Axial3D 06 Jan 2025
- Luminii provides CDD support to Maven on their investment in Connected Data 07 Oct 2024
- Private Equity's Relentless Focus on Driving Value Creation in Portfolio Companies 26 Sep 2024
- Luminii shortlisted as Commercial Due Diligence Provider of the Year at British Private Equity Awards 2024 10 Sep 2024